Brain Circulation

REVIEW ARTICLE
Year
: 2021  |  Volume : 7  |  Issue : 1  |  Page : 41--43

Exendin-4 for Parkinson's disease


Felipe de Jesús Esparza-Salazar, Alma Rosa Lezama-Toledo, Germán Rivera-Monroy, Cesario V Borlongan 
 Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Correspondence Address:
Cesario V Borlongan
Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL 33612
USA

This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.


How to cite this article:
Esparza-Salazar FJ, Lezama-Toledo AR, Rivera-Monroy G, Borlongan CV. Exendin-4 for Parkinson's disease.Brain Circ 2021;7:41-43


How to cite this URL:
Esparza-Salazar FJ, Lezama-Toledo AR, Rivera-Monroy G, Borlongan CV. Exendin-4 for Parkinson's disease. Brain Circ [serial online] 2021 [cited 2022 Jun 25 ];7:41-43
Available from: http://www.braincirculation.org/article.asp?issn=2394-8108;year=2021;volume=7;issue=1;spage=41;epage=43;aulast=Esparza-Salazar;type=0